<p>The license agreement allows Daiichi Sankyo to use the PER.C6 cell line in its early stage research to identify new antibodies and for the production of preclinical grade material. <br /><br />The PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies.<br /><br /><br /></p>